


CLAIMS

What is claimed is:

5

1. A compound of Formula I



I

or a pharmaceutically acceptable salt thereof,

wherein:

10 R¹ is independently selected from:

C₅ or C₆ cycloalkyl-(C₁-C₈ alkylene);

Substituted C₅ or C₆ cycloalkyl-(C₁-C₈ alkylene);

C₈-C₁₀ bicycloalkyl-(C₁-C₈ alkylene);

Substituted C₈-C₁₀ bicycloalkyl-(C₁-C₈ alkylene);

15 5- or 6-membered heterocycloalkyl-(C₁-C₈ alkylene);

Substituted 5- or 6-membered heterocycloalkyl-(C₁-C₈ alkylene);

8- to 10-membered heterobicycloalkyl-(C₁-C₈ alkylene);

Substituted 8- to 10-membered heterobicycloalkyl-(C₁-C₈ alkylene);

Phenyl-(C₁-C₈ alkylene);

20 Substituted phenyl-(C₁-C₈ alkylene);

Naphthyl-(C₁-C₈ alkylene);

Substituted naphthyl-(C₁-C₈ alkylene);

5- or 6-membered heteroaryl-(C₁-C₈ alkylene);

Substituted 5- or 6-membered heteroaryl-(C₁-C₈ alkylene);

25 8- to 10-membered heterobiaryl-(C₁-C₈ alkylene);

Substituted 8- to 10-membered heterobiaryl-(C₁-C₈ alkylene);

Phenyl;

Substituted phenyl;

Naphthyl;

Substituted naphthyl;
5- or 6-membered heteroaryl;
Substituted 5- or 6-membered heteroaryl;
8- to 10-membered heterobiaryl; and
5 Substituted 8- to 10-membered heterobiaryl;

R² is independently selected from:

H;
C₁-C₆ alkyl;
Phenyl-(C₁-C₈ alkylenyl);
10 Substituted phenyl-(C₁-C₈ alkylenyl);
Naphthyl-(C₁-C₈ alkylenyl);
Substituted naphthyl-(C₁-C₈ alkylenyl);
5- or 6-membered heteroaryl-(C₁-C₈ alkylenyl);
Substituted 5- or 6-membered heteroaryl-(C₁-C₈ alkylenyl);
15 8- to 10-membered heterobiaryl-(C₁-C₈ alkylenyl);
Substituted 8- to 10-membered heterobiaryl-(C₁-C₈ alkylenyl);
Phenyl-O-(C₁-C₈ alkylenyl);
Substituted phenyl-O-(C₁-C₈ alkylenyl);
Phenyl-S-(C₁-C₈ alkylenyl);
20 Substituted phenyl-S-(C₁-C₈ alkylenyl);
Phenyl-S(O)-(C₁-C₈ alkylenyl);
Substituted phenyl-S(O)-(C₁-C₈ alkylenyl);
Phenyl-S(O)₂-(C₁-C₈ alkylenyl); and
Substituted phenyl-S(O)₂-(C₁-C₈ alkylenyl);

25 Each substituted R¹ and R² group contains from 1 to 4 substituents, each independently on a carbon or nitrogen atom, independently selected from:

C₁-C₆ alkyl;
CN;
CF₃;
30 HO;
(C₁-C₆ alkyl)-O;
(C₁-C₆ alkyl)-S(O)₂;
H₂N;


(C₁-C₆ alkyl)-N(H);
(C₁-C₆ alkyl)₂-N;
(C₁-C₆ alkyl)-C(O)O-(C₁-C₈ alkylenyl)_m;
(C₁-C₆ alkyl)-C(O)O-(1- to 8-membered heteroalkylenyl)_m;
5 (C₁-C₆ alkyl)-C(O)N(H)-(C₁-C₈ alkylenyl)_m;
(C₁-C₆ alkyl)-C(O)N(H)-(1- to 8-membered heteroalkylenyl)_m;
H₂NS(O)₂-(C₁-C₈ alkylenyl);
(C₁-C₆ alkyl)-N(H)S(O)₂-(C₁-C₈ alkylenyl)_m;
(C₁-C₆ alkyl)₂NS(O)₂-(C₁-C₈ alkylenyl)_m;
10 3- to 6-membered heterocycloalkyl-(G)_m;
Substituted 3- to 6-membered heterocycloalkyl-(G)_m;
5- or 6-membered heteroaryl-(G)_m;
Substituted 5- or 6-membered heteroaryl-(G)_m;
(C₁-C₆ alkyl)-S(O)₂-N(H)-C(O)-(C₁-C₈ alkylenyl)_m; and
15 (C₁-C₆ alkyl)-C(O)-N(H)-S(O)₂-(C₁-C₈ alkylenyl)_m;


wherein each substituent on a carbon atom may further be independently selected from:

Halo; and

HO₂C;

20 wherein 2 substituents may be taken together with a carbon atom to which they are both bonded to form the group C=O;
wherein two adjacent, substantially sp² carbon atoms may be taken together with a diradical substituent to form a cyclic diradical selected from:





R is H or C₁-C₆ alkyl;

5 G is CH₂; O, S, S(O); or S(O)₂;

m is an integer of 0 or 1;

R⁷ is independently selected from the groups:

H;

CH₃;

10 CH₃O;

CH=CH₂;

HO;

CF₃;

CN;

15 HC(O);

CH₃C(O);

HC(NO_H);

H₂N;

(CH₃)-N(H);

20 (CH₃)₂-N;

H₂NC(O);

(CH₃)-N(H)C(O);

(CH₃)₂-NC(O);


halo; and



Y^6 and Y^8 are each independently CH_2 , C(O) , O , S , S(O) , S(O)_2 , or $\text{N(R}^5)$; or

R^7 and Y^8 may be taken together with the carbon atom to which they are both

5 attached to form a group selected from:



R^4 and R^5 are each independently selected from the groups:

H;

CH_3 ;

10 CH_3O ;

$\text{CH}=\text{CH}_2$;

HO ;

CF_3 ;

CN ;

15 HC(O) ;

$\text{CH}_3\text{C(O)}$;

HC(NOH) ;

H_2N ;

$(\text{CH}_3)\text{-N(H)}$;

20 $(\text{CH}_3)_2\text{-N}$;

$\text{H}_2\text{NC(O)}$;

$(\text{CH}_3)\text{-N(H)C(O)}$; and

$(\text{CH}_3)_2\text{-NC(O)}$;

Q is selected from:

25 OC(O) ;

$\text{CH(R}^6\text{)C(O)}$;


$\text{OC(NR}^6\text{)}$;

$\text{CH(R}^6\text{)C(NR}^6\text{)}$;


$\text{N(R}^6\text{)C(O)}$;

30 $\text{N(R}^6\text{)C(S)}$;


N(R⁶)C(NR⁶);
 N(R⁶)CH₂;
 SC(O);
 CH(R⁶)C(S);
 5 SC(NR⁶);
 trans-(H)C=C(H);
 cis-(H)C=C(H);
 C≡C;
 CH₂C≡C;
 10 C≡CCH₂;
 CF₂C≡C; and
 C≡CCF₂;




;




;




;




;



;



; and



;

15 Each R⁶ independently is H, C₁-C₆ alkyl, C₃-C₆ cycloalkyl; 3- to 6-membered heterocycloalkyl; phenyl; benzyl; or 5- or 6-membered heteroaryl;
 X is O, S, N(H), or N(C₁-C₆ alkyl);
 Each V is independently C(H) or N;
 wherein each C₈-C₁₀ bicycloalkyl is a bicyclic carbocyclic ring that contains 8-, 9-, or 10-member carbon atoms which are 5,5-fused, 6,5-fused, or 6,6-fused bicyclic rings, respectively, and wherein the ring is saturated or optionally contains one carbon-carbon double bond;
 wherein each 8- to 10-membered heterobicycloalkyl is a bicyclic ring that contains carbon atoms and from 1 to 4 heteroatoms independently selected from 2

O, 1 S, 1 S(O), 1 S(O)₂, 1 N, 4 N(H), and 4 N(C₁-C₆ alkyl), and wherein when two O atoms or one O atom and one S atom are present, the two O atoms or one O atom and one S atom are not bonded to each other, and wherein the ring is saturated or optionally contains one carbon-carbon or carbon-nitrogen double bond, and wherein the heterobicycloalkyl is a 5,5-fused, 6,5-fused, or 6,6-fused bicyclic ring, respectively,


5 wherein each heterocycloalkyl is a ring that contains carbon atoms and from 1 to 4 heteroatoms independently selected from 2 O, 1 S, 1 S(O), 1 S(O)₂, 1 N, 4 N(H), and 4 N(C₁-C₆ alkyl), and wherein when two O atoms or one O atom and one S atom are present, the two O atoms or one O atom and one S atom are not bonded to each other, and wherein the ring is saturated or 10 optionally contains one carbon-carbon or carbon-nitrogen double bond; wherein each 5-membered heteroaryl contains carbon atoms and from 1 to 4 heteroatoms independently selected from 1 O, 1 S, 1 N(H), 1 N(C₁-C₆ alkyl), and 4 N, and each 6-membered heteroaryl contains carbon atoms and 1 or 2 heteroatoms independently selected from N, N(H), and N(C₁-C₆ alkyl), and 5- and 6-membered heteroaryl are monocyclic rings;

15 wherein each heterobiaryl contains carbon atoms and from 1 to 4 heteroatoms independently selected from 1 O, 1 S, 1 N(H), 1 N(C₁-C₆ alkyl), and 4 N, and where the 8-, 9-, and 10-membered heterobiaryl are 5,5-fused, 6,5-fused, and 6,6-fused bicyclic rings, respectively, and wherein at least 1 of 20 the 2 fused rings of a bicyclic ring is aromatic, and wherein when the O and S atoms both are present, the O and S atoms are not bonded to each other;

25 wherein with any (C₁-C₆ alkyl)₂-N group, the C₁-C₆ alkyl groups may be optionally taken together with the nitrogen atom to which they are attached to form a 5- or 6-membered heterocycloalkyl; and wherein each group and each substituent recited above is independently selected.

30 2. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein each of Y⁶ and Y⁸ is independently CH₂ or S(O)₂.

3. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein R⁷ and Y⁸ are taken together with the carbon atom to which they are both attached to form a group selected from:




5

4. The compound according to Claim 1, wherein Q is C≡C.

5. The compound according to Claim 1, wherein Q is N(R⁶)C(O).

10 6. The compound according to any one of Claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R¹ is independently selected from:
Phenyl-(C₁-C₈ alkylenyl);
Substituted phenyl-(C₁-C₈ alkylenyl);
15 5- or 6-membered heteroaryl-(C₁-C₈ alkylenyl);
Substituted 5- or 6-membered heteroaryl-(C₁-C₈ alkylenyl);
8- to 10-membered heterobiaryl-(C₁-C₈ alkylenyl); and
Substituted 8- to 10-membered heterobiaryl-(C₁-C₈ alkylenyl); and
R² is independently selected from:
20 Phenyl-(C₁-C₈ alkylenyl)_m;
Substituted phenyl-(C₁-C₈ alkylenyl)_m;
5- or 6-membered heteroaryl-(C₁-C₈ alkylenyl)_m;
Substituted 5- or 6-membered heteroaryl-(C₁-C₈ alkylenyl)_m;
8- to 10-membered heterobiaryl-(C₁-C₈ alkylenyl)_m; and
25 Substituted 8- to 10-membered heterobiaryl-(C₁-C₈ alkylenyl)_m;
wherein m is an integer of 0 or 1; and
wherein each group and each substituent is independently selected.

7. The compound according to Claim 1 of Formula II



II

8. The compound according to Claim 7 selected from:

7-(3,5-Difluoro-4-hydroxy-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-

5 2H-pyrazino[1,2-c]pyrimidine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

7-Benzyl-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-3-carboxylic acid 3-methoxy-benzylamide;

7-(3,4-Difluoro-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-3-carboxylic acid (pyridin-4-ylmethyl)-amide;

10 7-Benzyl-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-3-carboxylic acid (pyridin-4-ylmethyl)-amide;

7-Benzyl-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-pyrazino[1,2-

15 c]pyrimidine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

7-(3,4-Difluoro-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

20 7-[4-(3-Ethyl-ureido)-benzyl]-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

7-(3,4-Difluoro-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-3-carboxylic acid 4-fluoro-

25 benzylamide;

6-Benzyl-8-methyl-5,7-dioxo-1,2,4a,5,6,7-hexahydro-2,6-naphthyridine-3-carboxylic acid 4-fluoro-benzylamide;

7-(4-Cyano-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-pyrazino[1,2-c]pyrimidine-3-carboxylic acid 4-fluoro-benzylamide;

7-(3,5-Difluoro-4-hydroxy-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-
5 pyrimido[6,1-c][1,4]oxazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

7-Benzyl-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]oxazine-3-carboxylic acid 3-methoxy-benzylamide;

7-(3,4-Difluoro-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-
10 pyrimido[6,1-c][1,4]oxazine-3-carboxylic acid (pyridin-4-ylmethyl)-amide;

7-Benzyl-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]oxazine-3-carboxylic acid (pyridin-4-ylmethyl)-amide;

7-Benzyl-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]oxazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;
15

7-(3,4-Difluoro-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]oxazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

7-[4-(3-Ethyl-ureido)-benzyl]-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-
20 pyrimido[6,1-c][1,4]oxazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

7-(3,4-Difluoro-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]oxazine-3-carboxylic acid 4-fluoro-benzylamide;
25

6-Benzyl-8-methyl-5,7-dioxo-4a,5,6,7-tetrahydro-1H-pyrano[4,3-c]pyridine-3-carboxylic acid 4-fluoro-benzylamide;

7-(4-Cyano-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]oxazine-3-carboxylic acid 4-fluoro-benzylamide;

7-(3,5-Difluoro-4-hydroxy-benzyl)-9-methyl-2,2,6,8-tetraoxo-1,6,7,8-tetrahydro-2H-2*t*⁶-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;
30

7-Benzyl-9-methyl-2,2,6,8-tetraoxo-1,6,7,8-tetrahydro-2H- $2l^6$ -pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid 3-methoxybenzylamide;

7-(3,4-Difluoro-benzyl)-9-methyl-2,2,6,8-tetraoxo-1,6,7,8-tetrahydro-2H- $2l^6$ -pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (pyridin-4-ylmethyl)-amide;

7-Benzyl-9-methyl-2,2,6,8-tetraoxo-1,6,7,8-tetrahydro-2H- $2l^6$ -pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (pyridin-4-ylmethyl)-amide;

7-Benzyl-9-methyl-2,2,6,8-tetraoxo-1,6,7,8-tetrahydro-2H- $2l^6$ -pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

7-(3,4-Difluoro-benzyl)-9-methyl-2,2,6,8-tetraoxo-1,6,7,8-tetrahydro-2H- $2l^6$ -pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

7-[4-(3-Ethyl-ureido)-benzyl]-9-methyl-2,2,6,8-tetraoxo-1,6,7,8-tetrahydro-2H- $2l^6$ -pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

7-(3,4-Difluoro-benzyl)-9-methyl-2,2,6,8-tetraoxo-1,6,7,8-tetrahydro-2H- $2l^6$ -pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid 4-fluorobenzylamide;

6-Benzyl-8-methyl-2,2,5,7-tetraoxo-1,2,4a,5,6,7-hexahydro- $2l^6$ -thiopyrano[4,3-c]pyridine-3-carboxylic acid 4-fluoro-benzylamide; and

7-(4-Cyano-benzyl)-9-methyl-2,2,6,8-tetraoxo-1,6,7,8-tetrahydro-2H- $2l^6$ -pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid 4-fluorobenzylamide;

or a pharmaceutically acceptable salt thereof.

30 9. The compound according to Claim 7 selected from:
7-(3,5-Difluoro-4-hydroxy-benzyl)-2-hydroxy-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H- $2l^4$ -pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

7-Benzyl-2-hydroxy-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-2*I*⁴-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid 3-methoxybenzylamide;

7-(3,4-Difluoro-benzyl)-2-hydroxy-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-2*I*⁴-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (pyridin-4-ylmethyl)-amide;

7-Benzyl-2-hydroxy-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-2*I*⁴-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (pyridin-4-ylmethyl)-amide;

7-Benzyl-2-hydroxy-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-2*I*⁴-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

7-(3,4-Difluoro-benzyl)-2-hydroxy-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-2*I*⁴-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

7-[4-(3-Ethyl-ureido)-benzyl]-2-hydroxy-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-2*I*⁴-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

7-(3,4-Difluoro-benzyl)-2-hydroxy-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-2*I*⁴-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid 4-fluorobenzylamide;

6-Benzyl-2-hydroxy-8-methyl-5,7-dioxo-1,2,4a,5,6,7-hexahydro-2*I*⁴-thiopyrano[4,3-c]pyridine-3-carboxylic acid 4-fluoro-benzylamide;

7-(4-Cyano-benzyl)-2-hydroxy-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-2H-2*I*⁴-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid 4-fluorobenzylamide;

7-(3,5-Difluoro-4-hydroxy-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

7-Benzyl-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid 3-methoxy-benzylamide;

7-(3,4-Difluoro-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (pyridin-4-ylmethyl)-amide;

7-Benzyl-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (pyridin-4-ylmethyl)-amide;

7-Benzyl-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

7-(3,4-Difluoro-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

7-[4-(3-Ethyl-ureido)-benzyl]-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide;

7-(3,4-Difluoro-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid 4-fluoro-benzylamide;

6-Benzyl-8-methyl-5,7-dioxo-4a,5,6,7-tetrahydro-1H-thiopyrano[4,3-c]pyridine-3-carboxylic acid 4-fluoro-benzylamide; and

7-(4-Cyano-benzyl)-9-methyl-6,8-dioxo-1,6,7,8-tetrahydro-pyrimido[6,1-c][1,4]thiazine-3-carboxylic acid 4-fluoro-benzylamide;

or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition, comprising a compound of Claim 1, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, excipient, or diluent.

11. The pharmaceutical composition according to Claim 10, comprising a compound according to Claim 8 or 9, or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, excipient, or diluent.

12. A method for treating osteoarthritis or rheumatoid arthritis, comprising administering to a patient suffering from osteoarthritis or rheumatoid arthritis a

nontoxic effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

13. The method according to Claim 12 wherein the compound of Claim 1 is a
5 compound of Claim 8 or 9.